$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000156459020038092 Filed on August 07, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.060M	$6.970M
YoY Change	-41.75%	-27.09%
% of Gross Profit
Research & Development	$3.700M	$7.340M
YoY Change	-49.59%	76.87%
% of Gross Profit
Depreciation & Amortization	$17.00K	$17.00K
YoY Change	0.0%	-32.0%
% of Gross Profit
Operating Expenses	$3.700M	$7.340M
YoY Change	-49.59%	-45.8%
Operating Profit
YoY Change
Interest Expense	-$300.0K	-$140.0K
YoY Change	114.29%
% of Operating Profit
Other Income/Expense, Net	-$301.0K	-$138.0K
YoY Change	118.12%	-200.73%
Pretax Income	-$7.890M	-$14.45M
YoY Change	-45.4%	7.76%
Income Tax
% Of Pretax Income
Net Earnings	-$7.887M	-$14.45M
YoY Change	-45.41%	7.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$196.6K	-$398.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.12M	$76.30M
YoY Change	-51.35%	20.33%
Cash & Equivalents	$30.35M	$49.33M
Short-Term Investments	$6.770M	$26.97M
Other Short-Term Assets	$1.850M	$1.440M
YoY Change	28.47%	157.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$38.97M	$77.74M
YoY Change	-49.87%	21.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$165.0K	$214.0K
YoY Change	-22.9%	-29.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$110.0K	$100.0K
YoY Change	10.0%
Total Long-Term Assets	$950.0K	$1.303M
YoY Change	-27.09%	331.46%
TOTAL ASSETS
Total Short-Term Assets	$38.97M	$77.74M
Total Long-Term Assets	$950.0K	$1.303M
Total Assets	$39.92M	$79.04M
YoY Change	-49.49%	22.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$770.0K	$2.473M
YoY Change	-68.86%	17.87%
Accrued Expenses	$3.485M	$5.773M
YoY Change	-39.63%	155.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.149M	$2.231M
YoY Change	130.79%
Total Short-Term Liabilities	$10.77M	$10.99M
YoY Change	-2.03%	152.36%
LONG-TERM LIABILITIES
Long-Term Debt	$8.704M	$12.31M
YoY Change	-29.27%
Other Long-Term Liabilities	$160.0K	$520.0K
YoY Change	-69.23%
Total Long-Term Liabilities	$8.704M	$12.31M
YoY Change	-29.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.77M	$10.99M
Total Long-Term Liabilities	$8.704M	$12.31M
Total Liabilities	$19.63M	$23.30M
YoY Change	-15.75%	434.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$158.9M	-$112.5M
YoY Change	41.23%	84.57%
Common Stock		$169.3M
YoY Change		39.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.29M	$55.22M
YoY Change
Total Liabilities & Shareholders Equity	$39.92M	$79.04M
YoY Change	-49.49%	22.98%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$7.887M	-$14.45M
YoY Change	-45.41%	7.78%
Depreciation, Depletion And Amortization	$17.00K	$17.00K
YoY Change	0.0%	-32.0%
Cash From Operating Activities	-$6.320M	-$9.620M
YoY Change	-34.3%	13.04%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$11.25M	-$26.85M
YoY Change	-141.9%
Cash From Investing Activities	$11.25M	-$26.85M
YoY Change	-141.9%	67025.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-460.0K	41.22M
YoY Change	-101.12%	-23.2%
NET CHANGE
Cash From Operating Activities	-6.320M	-9.620M
Cash From Investing Activities	11.25M	-26.85M
Cash From Financing Activities	-460.0K	41.22M
Net Change In Cash	4.470M	4.750M
YoY Change	-5.89%	-89.47%
FREE CASH FLOW
Cash From Operating Activities	-$6.320M	-$9.620M
Capital Expenditures		$0.00
Free Cash Flow		-$9.620M
YoY Change		13.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q1	elox	Restructuring And Related Costs Severance Cost Payment Period RestructuringAndRelatedCostsSeveranceCostPaymentPeriod	P1Y
	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P3Y8M26D
	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P3Y2M26D
	elox	Class Of Warrant Or Right Exercisable Expiration Period ClassOfWarrantOrRightExercisableExpirationPeriod	P3Y2M26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M14D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y8M1D
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	36213000
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2658000
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-11917000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	34433000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26288000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-480000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36098171
	us-gaap	Net Income Loss NetIncomeLoss	-21833000
	us-gaap	Net Income Loss NetIncomeLoss	-26366000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-5000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	24000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21838000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26342000
	us-gaap	Profit Loss ProfitLoss	-21833000
	us-gaap	Profit Loss ProfitLoss	-26366000
	us-gaap	Share Based Compensation ShareBasedCompensation	5971000
	us-gaap	Share Based Compensation ShareBasedCompensation	5674000
	us-gaap	Depreciation Depreciation	36000
	us-gaap	Depreciation Depreciation	50000
	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	246000
	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	231000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	301000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	234000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	109000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	449000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-339000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1726000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-281000
	elox	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-231000
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-79000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18812000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	33590000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6750000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000
	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	9000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26865000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	276000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2083000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	455000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1120000
	elox	Proceeds From Advances From Collaboration Partners ProceedsFromAdvancesFromCollaborationPartners	402000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46397000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	720000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49371000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49326000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	45000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49371000
	us-gaap	Interest Paid Net InterestPaidNet	400000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	79000
	elox	Noncash Acquisition Of Treasury Shares NoncashAcquisitionOfTreasuryShares	95000
	elox	Non Cash Issuance Of Shares Upon Exercise Of Warrants NonCashIssuanceOfSharesUponExerciseOfWarrants	178000
	elox	Fair Value Of Warrants Issued In Connection With Long Term Debt FairValueOfWarrantsIssuedInConnectionWithLongTermDebt	421000
	elox	Non Cash Deferred Public Offering Costs In Accounts Payable And Accruals NonCashDeferredPublicOfferingCostsInAccountsPayableAndAccruals	172000
CY2020Q1	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-116000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3995000
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	47000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13946000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	26257000
CY2020Q2	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-3000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1976000
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-52000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-7887000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	20291000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	42911000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	421000
CY2019Q1	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-121000
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90000
CY2019Q2	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-111000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3016000
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	23000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-14449000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	55224000
	elox	Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons	1800
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158900000
CY2020Q2	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	37100000
CY2020Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1000
CY2019Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	26000
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2020Q2	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	921000
CY2019Q4	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	448000
CY2020Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	649000
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	699000
CY2020Q2	us-gaap	Prepaid Insurance PrepaidInsurance	229000
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	217000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1800000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1390000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	446000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	488000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	281000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	287000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000
CY2020Q2	us-gaap	Depreciation Depreciation	17000
CY2019Q2	us-gaap	Depreciation Depreciation	17000
	us-gaap	Depreciation Depreciation	36000
	us-gaap	Depreciation Depreciation	50000
CY2020Q2	elox	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	936000
CY2019Q4	elox	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1560000
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1070000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2200000
CY2020Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	958000
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	424000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	664000
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	137000
CY2020Q2	elox	Accrued Interest On Debt AccruedInterestOnDebt	63000
CY2019Q4	elox	Accrued Interest On Debt AccruedInterestOnDebt	94000
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3485000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4655000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2589000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5531000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5177000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	417000
CY2020Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13714000
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	761000
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	12953000
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5149000
CY2020Q2	elox	Long Term Debt Maturities Final Fee Due LongTermDebtMaturitiesFinalFeeDue	-900000
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8704000
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40834
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	400000
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	323894
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.32
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	323894
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.32
CY2020Q2	elox	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	323894
CY2020Q2	elox	Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice	4.32
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4737670
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.17
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3629073
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1360910
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.54
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10636
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1135714
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.08
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4952230
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.18
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	857311
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2497570
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.72
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	772603
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5971000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5674000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30347000
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	30347000
CY2020Q2	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost	37103000
CY2020Q2	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000
CY2020Q2	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	37116000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22493000
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	22493000
CY2019Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost	56258000
CY2019Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000
CY2019Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2019Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	56276000
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2020Q2	elox	Fair Value Assets Transfers Between Level2 And Level3 Description FairValueAssetsTransfersBetweenLevel2AndLevel3Description	the Company did not have any transfers of financial assets between Level 2 and 3
	elox	Fair Value Assets Transfers Between Level2 And Level3 Description FairValueAssetsTransfersBetweenLevel2AndLevel3Description	the Company did not have any transfers of financial assets between Level 2 and 3
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-7887000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-14449000
	us-gaap	Net Income Loss NetIncomeLoss	-21833000
CY2020Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	69000
CY2019Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	206000
	us-gaap	Interest And Other Income InterestAndOtherIncome	313000
	us-gaap	Interest And Other Income InterestAndOtherIncome	494000
CY2020Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12000
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	31000
CY2020Q2	us-gaap	Investment Income Net InvestmentIncomeNet	-11000
CY2019Q2	us-gaap	Investment Income Net InvestmentIncomeNet	130000
	us-gaap	Investment Income Net InvestmentIncomeNet	-9000
	us-gaap	Investment Income Net InvestmentIncomeNet	133000
CY2020Q2	us-gaap	Interest Expense Other InterestExpenseOther	347000
CY2019Q2	us-gaap	Interest Expense Other InterestExpenseOther	482000
	us-gaap	Interest Expense Other InterestExpenseOther	762000
	us-gaap	Interest Expense Other InterestExpenseOther	736000
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-301000
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-138000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-480000
	us-gaap	Net Income Loss NetIncomeLoss	-26366000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40129304
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36278567
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40101789
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36098171
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5643291
CY2020Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	13
CY2020Q1	us-gaap	Severance Costs1 SeveranceCosts1	4000000.0
CY2020Q1	elox	Restructuring And Related Cost Stock Based Compensation Expense RestructuringAndRelatedCostStockBasedCompensationExpense	2100000
	us-gaap	Restructuring Charges RestructuringCharges	1870000
	us-gaap	Payments For Restructuring PaymentsForRestructuring	912000
CY2020Q2	us-gaap	Restructuring Reserve RestructuringReserve	958000

Files In Submission

Name	View Source	Status
0001564590-20-038092-index-headers.html	Edgar Link	pending
0001564590-20-038092-index.html	Edgar Link	pending
0001564590-20-038092.txt	Edgar Link	pending
0001564590-20-038092-xbrl.zip	Edgar Link	pending
elox-10q_20200630.htm	Edgar Link	pending
elox-10q_20200630_htm.xml	Edgar Link	completed
elox-20200630.xsd	Edgar Link	pending
elox-20200630_cal.xml	Edgar Link	unprocessable
elox-20200630_def.xml	Edgar Link	unprocessable
elox-20200630_lab.xml	Edgar Link	unprocessable
elox-20200630_pre.xml	Edgar Link	unprocessable
elox-ex311_7.htm	Edgar Link	pending
elox-ex312_9.htm	Edgar Link	pending
elox-ex321_6.htm	Edgar Link	pending
elox-ex322_8.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2020 Q2 Form 10-Q Financial Statement

#000156459020038092 Filed on August 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2020 Q2 Form 10-Q Financial Statement

#000156459020038092 Filed on August 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox